van Noort PI, Tena-Sempere M. Characterization of the inhibitory roles of RFRP3, the mammalian ortholog of GnIH, in the control of gonadotropin secretion in the rat: in vivo and in vitro studies. Am J Physiol Endocrinol Metab 299: E39 -E46, 2010. First published April 27, 2010; doi:10.1152/ajpendo.00108.2010.-RF-amide related peptides (RFRP), as putative mammalian orthologs of the avian gonadotropin-inhibitory hormone (GnIH), have been proposed as key regulators of gonadotropin secretion in higher vertebrates. Yet considerable debate has arisen recently on their physiological relevance and potential mechanisms and sites of action. Present studies were undertaken to further characterize the effects of RFRP on LH and FSH secretion by a combination of in vivo and in vitro approaches in male and female rats. Initial screening via intracerebroventricular (icv) administration of different analogs of RFRP1 (RFRP1-12 and RFRP1-20) and RFRP3 (RFRP3-8 and RFRP3-17), as well as the related neuropeptide FF (NPFF8), to gonadectomized (GNX) female rats evidenced significant, albeit modest, inhibitory effects on LH secretion only for RFRP3-8 and RFRP3-17, which were detectable at the high dose rage (1 nmol for RFRP3-8, 5 nmol for RFRP3-17). This moderate inhibitory action was also documented after icv administration of RFRP3-8 to intact and GNX male rats. In addition, systemic (intravenous) administration of RFRP3-8 decreased the circulating levels of both gonadotropins in GNX male rats. Likewise, RFRP3-8 inhibited basal and GnRH-stimulated LH secretion by pituitaries from GNX males in vitro. This inhibitory effect was blocked by the antagonist of RFRP receptors, RF9. In summary, our results support a putative inhibitory role of RFRP3 as ortholog of GnIH in the regulation of gonadotropin secretion in mammals, which appears to involve direct pituitary actions as well as potential central (hypothalamic) effects.
THE NEUROENDOCRINE CONTROL of the gonadotropic axis relies on a complex array of stimulatory and inhibitory signals that primarily, but not exclusively, impinge onto a subset of hypothalamic neurons producing the decapeptide gonadotropinreleasing hormone (GnRH) (7, 15) . Our knowledge on the nature and mechanisms of action of these neuroendocrine regulators has enlarged considerably recently, with the identification of novel factors (e.g., kisspeptins) and unsuspected biological effects of classical signals (e.g., excitatory actions of putative inhibitory neurotransmitters such as GABA) (7, 22) . In this context, a 12-amino acid neuropeptide, with a distinctive RF-amide (RFa) motif at its COOH terminus, was isolated from the avian brain in 2000 and termed gonadotropin-inhibitory hormone (GnIH) due to its capacity to suppress gonadotropin release by quail pituitaries (30) . This finding boosted a considerable interest in the field, as this was thought to represent the physiological counterpart of GnRH or one of its major inhibitors. This interest was increased further in 2006, when Kriegsfeld et al. (13) proposed that the structurally related RF-amide related peptides (RFRPs) are the mammalian counterparts of avian GnIH, thus potentially playing a role in the inhibitory control of gonadotropin secretion in higher vertebrates.
Two major forms of RFRP, RFRP1 and RFRP3, have been identified as major cleavage products of a single RFRP gene (3, 8) . These peptides have been shown to have sequence homology with neuropeptides FF (NPFF) and AF (NPAF), also members of the limited family of RFa peptides in mammals (8) . To date, the amino acid sequence of the precursor and/or mature forms of RFRP has been defined (or predicted) from a large number of species, including primates, sheep, cattle, and laboratory rodents (3, 29) . Of note, RFRP-1 has been shown to display a higher degree of homology with avian GnIH than with RFRP3, and its mature form has been predicted to be composed by either 12 (e.g., human, rat, mouse) or 34 (e.g., cattle, sheep) amino acids sharing the COOH terminus (3) . Likewise, mammalian RFRP3 has been shown to exist as mature peptide of different extensions of a common COOH terminus with either 8 (e.g., human, sheep), 17 (e.g., mouse), 18 (e.g., rat), or 28 (e.g., cattle) amino acids (3) . The biological actions of these peptides are preferentially conducted via the surface receptors (RFRPR; also termed NPFF1R or GPR147) (2, 3, 32) . In contrast, NPFF and NPAF bind and activate the structurally related receptor (NPFFR; also termed NPFF2R) (2, 3, 32) .
Departing from the original work proposing RFRPs as functional counterparts of GnIH in mammals (13) , during the last three years a number of studies aiming to characterize the patterns of brain expression as well as the effects and mechanisms of action of RFRPs in different mammalian species have been produced (1, 4 -6, 9 -12, 14, 16, 20, 21, 26, 28) . Among those, functional studies have been conducted mostly in sheep and rodents and have preferentially targeted LH secretory responses and eventual direct brain or pituitary effects of RFRP3 (1, 4, 10, 16, 26) . Overall, the available data point out that RFRPs may participate in the inhibitory control of the gonadotropic axis in higher vertebrates (3) . Yet meta-analysis of the available experimental evidence reveals some notable discrepancies regarding the magnitude, sites of action, and physiological relevance of the biological effects of RFRP, which may stem from differences in species, experimental models, dose regimens, and methodological approaches used across the studies. As an illustration of such controversy, either lack of effects or inhibitory actions (of variable magnitude) on circulating LH levels have been reported following intracerebroventricular (icv) injection of RFRP3 (1, 10, 13, 16) . Similarly, a few studies have been able to demonstrate direct pituitary effects of RFRP3 in terms of inhibition of gonadotropin synthesis and secretion (4, 11, 16) , but this finding has not been replicated by others (1) .
In this scenario, our present studies were undertaken to provide an integral characterization of the effects of RFRP1 and RFRP3 on LH and FSH secretion by a combination of in vivo and in vitro approaches in male and female rats. Because initial in vivo testing involving central (icv) injection of different peptides variants suggested a predominant inhibitory action of RFRP3 (and especially its octapeptide form RFRP3-8), further testing was conducted in gonadal-intact and/or gonadectomized (GNX) male and female rats. In addition, the effects of systemic administration of RFRP3-8 and its potential actions on basal and GnRH-stimulated gonadotropin secretion directly at the pituitary level were also evaluated.
MATERIALS AND METHODS

Animals and drugs.
Wistar rats bred in the vivarium of the University of Córdoba were used. The animals were maintained under constant conditions of light (14 h of light, from 0700) and temperature (22°C) and housed in groups of four rats per cage until the beginning of the pharmacological tests, with free access to pelleted food and tap water. Experimental procedures were approved by the Córdoba University Ethics Committee for animal experimentation and conducted in accordance with the European Union normative for care and use of experimental animals. The peptide compounds used in the present study, and their corresponding amino acid sequences, are summarized in Table 1 . These included 1) the analogs of RFRP1, RFRP1-12, and RFRP1-20 and 2) the analogs of RFRP3, RFRP3-8, and RFRP3-17. In addition, for comparative purposes, 3) the analog of the structurally related NPFF, NPFF 8, was also included in the initial testing. Finally, the antagonist of RFRPR (and NPFFR), RF9 (27) , was used selectively in some in vitro studies. These peptide analogs were synthesized and supplied by Merck Sharp & Dohme (MSD; Oss, The Netherlands). GnRH was purchased from Sigma Chemical (St. Louis, MO).
Experimental designs. In experiment 1, the effects of different analogs of RFRP, as selective agonists of RFRPR, on gonadotropin secretion were evaluated. To target central neuroendocrine pathways, a protocol of icv injection of the compounds was implemented as described elsewhere (17, 18) . In detail, the effects on LH and FSH levels of central administration of the RFRP1 analogs RFRP1-20 and RFRP1-17 as well as the RFRP3 analogs RFRP3-17 and RFRP3-8 were evaluated in adult GNX female rats, with GNX being performed 2 wk before conduction of the experiments. In addition, the effects of icv injection of NPFF8, agonist of NPFFR, were tested using a similar experimental setting. A dose of 1 nmol of each agonist (in 10 l of saline) per rat was injected icv (except for RFRP3-17, for which 1 and 5 nmol doses were tested), and blood samples (250 l) were obtained by jugular venipuncture under light ether anesthesia before (0 min) and at 15, 30, 60, and 120 min after icv administration, in keeping with our previous references (19, 23, 24) . Animals injected with vehicle (0.9% NaCl) served as controls.
Initial analyses identified RFRP3, but not RFRP1, as putative inhibitor of gonadotropin secretion in rats. Moreover, RFRP3-8 was found to be effective at lower doses than was RFRP3-17. On this basis, in experiment 2, a detailed dose-response study of the effects of RFRP3-8 on gonadotropin secretion was conducted in adult male rats. Groups of adult male rats (n ϭ 10/group) were implanted with icv cannulae as described above, and RFRP3-8 was centrally injected over a range of doses (0.1, 0.5, 1, and 5 nmol in 10 l of saline). Blood samples (250 l) were obtained by jugular venipuncture before (0 min) and at 15, 30, 60, and 120 min after icv injection. Using a similar protocol, in experiment 3, the effects of a similar range of doses of RFRP3-8 were tested in groups (n ϭ 10/group) of adult GNX male rats, with GNX being performed 2 wk before conduction of experiments. Rats injected with physiological saline served as controls. All tests were carried out between 0900 and 1000.
In addition to central effects, systemic or direct pituitary actions of RFRP3 were assayed in the last series of experiments. Thus, in experiment 4, the effects of systemic [intravenous (iv)] administration of RFRP3-8 to adult GNX male rats under freely moving conditions were assayed. To this end, groups of animals (n ϭ 10) were implanted with intracardiac cannulae under pentobarbital sodium (50 mg/kg) anesthesia. After surgery, the animals were individually caged and subjected to daily anticoagulant treatment for 5 days. Hormonal tests consisted of iv administration of a single bolus of RFRP3-8 (10 nmol in 200 l of saline) and regular blood sampling in conscious conditions before (0 min) and 30, 60, 75, 90, and 120 min after iv injection. In addition, in experiment 5, direct pituitary effects of RFRP3 were evaluated. To this end, static incubations of pituitary tissue from adult GNX male rats were carried out. Procedures for incubation of hemipituitary explants were as described in detail elsewhere (18) . Briefly, upon decapitation of the animals, anterior pituitaries were excised, halved (n ϭ 12 hemipituitaries/group), and placed in scintillation vials in a Dubnoff shaker at 37°C with constant shaking (60 cycles/min) under an atmosphere of 95% O 2-5% CO2. After 1 h of preincubation, the media were replaced by either fresh medium alone (DMEM) or medium containing increasing doses of RFRP3-8 (10 Ϫ10 , 10 Ϫ8 , and 10 Ϫ6 M). Samples from the incubation media were collected at 120 min for hormone determinations. Similarly, the effects of the same range of doses of RFRP3-8 were assayed in GnRH-stimulated (10 Ϫ9 M) conditions, following a similar incubation protocol. In the same setting, the specificity for the effects of RFRP3-8 on GnRH-stimulated secretion was also tested. To this end, hemipituitaries, challenged with GnRH (10 Ϫ9 M) alone or in combination with a fixed concentration of RFRP3-8 (10 Ϫ8 M), were coexposed to the antagonists of RFRP (and NPRR) receptors RF9 (10 Ϫ6 M) (27) . Hormone determinations were conducted at 120 min after the beginning of the incubations. Hemipituitaries incubated with DMEM alone served as controls.
Gonadotropin measurements by specific radioimmunoassay. Serum LH and FSH levels were determined in a volume of 25-50 l using a double-antibody method and radioimmunoassay kits supplied by the National Institutes of Health (Dr. A. F. Parlow; National Institute of Diabetes and Digestive and Kidney Diseases National Hormone and Peptide Program, Torrance, CA). Rat LH-I-10 and FSH-I-9 were labeled with 125 I using Iodo-gen tubes, following the instructions of the manufacturer (Pierce, Rockford, IL). Hormone concentrations were expressed using reference preparations LH-RP-3 and FSH-RP-2 as standards. Intra-and interassay coefficients of variation were, respectively, Ͻ8 and 10% for LH and Ͻ6 and 9% for FSH. The sensitivity of the assay was 5 pg/tube for LH and 20 pg/tube for FSH. Accuracy of hormone determinations was confirmed by assessment of rat serum samples of known concentrations (external controls).
Presentation of data and statistics. Hormonal determinations were conducted in duplicate, with a minimal total number of 10 samples per group. When appropriate, integrated gonadotropin secretory responses were also calculated as the area under the curve (AUC), following the trapezoidal rule, in agreement with previous references (19, 23, 24) . Results were analyzed for statistically significant differences using single or repeated-measures ANOVA followed by Student-NewmanKeuls multiple range test (SigmaStat 2.0; Jandel, San Rafael, CA). Unless stated otherwise for specific in vivo experiments (e.g., experiment 4), due to the large number of data points to be analyzed per experiment, and to ease presentation and discussion of results, we showed statistical analyses only for acute responses (15 min) and AUC data. P Յ 0.05 was considered significant.
RESULTS
Central injection of RFRP3 modestly inhibits gonadotropin secretion in male and female rats.
The effects of RFRP1 and RFRP3, as well as the related NPFF, were initially explored in the model of adult GNX female rats. This was selected on the basis of previous literature to ease identification of potential inhibitory actions of RFRPs (13) . Similarly, based on previous reports on the hypothalamic expression and actions of RFRPs (3), a central (icv) route of administration was chosen, and a single bolus of 1 nmol of each compound (i.e., in the high dose range) was tested individually. Despite hormonal testing of different analogs of RFRP1 (RFRP1-12 and RFRP1-20) and RFRP3 (RFRP3-8 and RFRP3-17) as well as NPFF8 in our assays, only RFRP3-8 was able to evoke, at the dose of 1 nmol/icv, a significant (ϳ45%) drop in circulating LH levels, which was transient and detected solely at 15 min after icv injection of the compound (Fig. 1A) . This is compatible with the in vitro half-life of RFRP3-8 in rat serum, which is 14.3 min (data not shown). In contrast, none of the peptides tested was capable, at the dose of 1 nmol, of significantly modifying serum FSH levels in GNX female rats at any of the time points studied (Fig. 1B) . Because RFRP3-17 was not able to mimic the effects of the related peptide RFRP3-8 on serum LH levels, specific analyses on this compound were extended. As shown in Fig. 2A , at the dose of 5 nmol icv, but not at 1 nmol, RFRP3-17 induced a variable degree of suppression of circulating LH levels at all of the time points studied (Յ120 min after injection). This resulted in a consistent ϳ25% reduction in integrated LH levels, calculated as AUC over the 120-min study period following RFRP3-17 injection. Again, neither 1-nor 5-nmol doses of RFRP3-17 were capable of significantly modifying the circulating concentrations of FSH following its icv injection into GNX female rats at any time point studied (Fig. 2B) .
To further document the inhibitory actions of RFRP3 on gonadotropin secretion, detailed dose-response analyses were conducted in adult male rats either gonadally intact or after being GNX. Individual profiles, acute secretory changes (at 15 min), and integrated LH and FSH responses to increasing doses of RFRP3-8 (0.1, 0.5, 1, and 5 nmol icv) in intact male rats are shown in Fig. 3 . To ease comparison, statistical analyses were conducted on acute and integrated AUC responses to the range of doses of RFRP3-8 tested over the corresponding study period (120 min). Despite the low prevailing concentrations of gonadotropins in intact males, significant decreases of LH levels were detected following icv injection of RFRP3-8, but only at the high dose range (acute responses: 5 nmol; AUC responses: 1 and 5 nmol; Fig. 3A) . A similar inhibitory action of RFRP3-8 was also observed at integrated (AUC) FSH levels, but only with the dose of 5 nmol (Fig. 3B) . Grossly similar profiles of responses to icv injection of RFRP3-8 were detected in GNX male rats despite the prevailing increase in circulating gonadotropin levels. As shown in Fig. 4A , increasing doses of RFRP3-8 evoked a decrease in the circulating levels of LH, as estimated by AUC secretory mass over the 120-min study period, which became significant only for the 5-nmol dose. Likewise, serum LH levels tended to be lower also at 15 min after icv injection of the highest doses of RFRP3-8 (1 and 5 nmol), although this trend did not reach statistical significance. In addition, a reduction in acute and AUC secretion of FSH was detected only following icv injection of the highest dose (5 nmol) of RFRP3-8 tested (Fig. 4B) .
Systemic and pituitary effects of RFRP3 on gonadotropin secretion: evidence for inhibitory actions. In addition to its central inhibitory actions, the potential effects of systemic administration of RFRP3-8 on gonadotropin secretion were also explored as a means to tease apart brain (hypothalamic) vs. peripheral (pituitary) effects of the peptide in the control of gonadotropin secretion. As a complementary approach, the direct pituitary effects of RFRP3-8 on LH and FSH secretion by tissue explants were also monitored in vitro in both basal and GnRH-stimulated conditions.
The effects of systemic administration of RFRP3-8 on gonadotropin secretion were explored in GNX male rats following iv administration of a single bolus of the peptide (10 nmol in 200 l). Blood sampling was conducted at 15-to 30-min intervals under freely moving conditions along with the 120-min period following the iv injection of the peptide. As shown in Fig. 5 , systemic administration of RFRP3-8 induced a moderate but detectable decrease of serum LH and FSH concentrations over the corresponding levels in vehicle-injected animals as well as vs. basal preinjection values. In detail, LH levels were significantly lower at 30 and 60 min after iv injection of RFRP3-8 (when compared with basal concentrations; Fig. 5A ), whereas FSH levels were decreased between 60 and 90 min following RFRP3-8 administration (Fig. 5B ). Yet due to hormone fluctuations in vehicle-injected animals, statistically significant differences vs. the vehicle group were achieved only at 60 min for LH and between 60 and 75 min for FSH. In addition, integral (AUC) LH and FSH responses to iv injection of RFRP3-8 were calculated over the first 75 min; this time frame was selected on the basis of the observed profile of gonadotropin responses and the short half-life of RFRP3-8 in rat serum. A trend toward reduction in AUC secretion of gonadotropins was detected after iv injection of RFRP3-8 (ϳ20 and 10% decreases for LH and FSH, respectively), which reached statistical significance for LH only (Fig.  5, A and B) .
In addition, the potential direct pituitary effects of RFRP3-8 were evaluated using static incubations of pituitary tissue from GNX male rats challenged with increasing concentrations of RFRP3-8 (10 Ϫ10 , 10 Ϫ8 , and 10 Ϫ6 M) in vitro. In basal conditions, RFRP3-8 induced a dose-dependent decrease in LH secretion, which became statistically significant only from the dose of 10 Ϫ8 M onward (Fig. 6A) . In contrast, none of the doses tested was capable of modifying basal FSH secretion in vitro (Fig. 6B ). In addition, the ability of increasing doses of RFRP3-8 to modify GnRH-stimulated gonadotropin secretion in vitro was also monitored. As shown in Fig. 7A, 10 Ϫ9 M GnRH elicited the expected increase in LH secretion to the incubation media, a response that was significantly obliterated by the coexposure to RFRP3-8. However, this inhibitory action displayed an inverted dose-dependent relationship, since it was detected for the doses of 10 Ϫ10 and 10 Ϫ8 M but not for the dose of 10 Ϫ6 M RFRP3-8. Notably, none of the doses of RFRP3-8 tested was able to significantly alter GnRH-stimulated FSH secretion in vitro (data not shown). Finally, specificity of the inhibitory action of RFRP3-8 on pituitary LH secretion was confirmed in vitro using a similar setting and the antagonist of RFRP (and NPFF) receptors, RF9. As shown in Fig. 7B , the inhibitory effect of 10 Ϫ8 M RFRP3-8 on GnRHstimulated LH secretion was totally prevented by coexposure to an effective concentration (10 Ϫ6 M) of RF9; the antagonist alone was unable to modify the magnitude of LH secretory responses to GnRH in vitro.
DISCUSSION
Identification of GnIH in the avian brain (30) and the subsequent characterization of RFRP as its putative ortholog in mammals (13) raised considerable interest and opened up new pathways for our understanding of the neuroendocrine mechanisms controlling gonadotropin secretion. However, although several studies on this topic have been produced during the last three years, characterization of the physiological roles and mechanisms of action of these neuropeptides, as putative inhibitors of the gonadotropic axis in mammals, remains so far incomplete (3). In fact, although pharmacological tests and expression analyses have been conducted in a variety of species, clear controversy persists on the magnitude, major sites of action, and physiological relevance of the effects of these neuropeptides. Such apparent discrepancies may stem from the use of different species (functional tests have been reported in rats, mice, sheep, and cattle), RFRP analogs (RFRP1 vs. RFRP3, with different amino acid lengths each), developmental stages (pubertal vs. adult animals), experimental models (gonadal-intact vs. GNX animals), routes of administration (icv vs. iv administration in vivo, direct pituitary actions in vitro), time course for analysis, and even hormonal end points (most studies targeted LH, whereas only few assayed FSH responses also). To contribute to clarify the above uncertainties, and to extend the pharmacological characterization of different analogs of RFRP, the present work was undertaken in an attempt to provide an integral analysis of the effects of RFRP1 and RFRP3 on LH and FSH secretion in male and female rats under different experimental conditions (i.e., gonadal intact or GNX) and through a combination of in vivo and in vitro approaches.
Initial hormonal testing, using GNX female rats as a means to ease identification of potential inhibitory effects against the prevailing elevated levels of gonadotropins, revealed consistent, albeit modest, inhibitory effects of RFRP3 but not of RFRP1 analogs on LH and/or FSH levels; NPFF was devoid of any discernible inhibitory actions on gonadotropin secretion in this model. This is congruent with most of the previous literature, which has documented the ability of RFRP3 to inhibit LH secre- tion under some conditions (3), whereas the putative gonadotropin-inhibitory actions of RFRP1 remained as yet scarcely evaluated. Our results, testing two different analogs of RFRP1, cast doubt on the possibility that, even at high doses, this neuropeptide may operate centrally to control gonadotropin secretion (see Fig. 1 ), a contention that was reinforced by our preliminary icv testing of 5-nmol doses of RFRP1-12 and RFRP1-20 (unpublished data). Intriguingly, RFRP1 has been shown to display a higher degree of homology with avian GnIH than RFRP3 (3), yet the latter seems to be the functional counterpart of GnIH in mammals. On this basis, further pharmacological tests were conducted using the octapeptide form of RFRP3, in keeping with previous studies in ovine and bovine species (4, 11) , since this peptide fragment appears to have higher biopotency than the larger 17-amino acid fragment of RFRP3 in the rat. Admittedly, our current data cannot exclude other potential neuroendocrine effects of RFRP1. In fact, the ability of this peptide to elicit PRL secretion has been documented previously (25) , yet our procedure for repeated blood sampling did not allow us to conduct reliable PRL determinations in our experimental groups.
The ability of central injection of RFRP3-8 to inhibit LH secretion was demonstrated not only in GNX female rats, in line with previous data (13) , but also in intact and GNX male rats; characterization of gonadotropin responses to icv administration of RFRP3 in the male had so far received little attention. Also of interest, our study is the first to disclose inhibitory actions of centrally injected RFRP3 on FSH secretion in male rats. Although in our experiments the nature of gonadotropin responses to RFRP3-8 (inhibition) was unambiguous, the magnitude of such responses was somewhat modest and detected only at the high dose range (Ն1 nmol/rat). A tempting possibility for such a state of low responsiveness is that the endogenous tone of RFRP3/GnIH is constitutively Fig. 7 . Direct pituitary effects of RFRP3-8 on gonadotropin-releasing hormone (GnRH)-stimulated gonadotropin secretion. The effects of RFRP3-8 on GnRH-stimulated gonadotropin secretion in vitro were evaluated using hemipituitaries from adult GNX male rats challenged with increasing concentrations (10 Ϫ10 , 10
Ϫ8
, and 10 Ϫ6 M) of RFRP3-8 in the presence of a fixed concentration (10 Ϫ9 M) of GnRH. In addition, the specificity for the observed effects of RFRP3-8 was also assayed using a similar procedure; hemipituitaries from adult GNX male rats were challenged with fixed concentrations of RFRP3-8 (10 Ϫ8 M) or GnRH (10 Ϫ9 M) and were coincubated with the antagonist of RFRP receptors RF9 (10 Ϫ6 M). Hormonal responses were assayed at 120 min of incubation. Groups with different letters are statistically different (ANOVA followed by Student-Newman-Keuls multiple range test). elevated, thus masking the potential inhibitory effects of a pharmacological stimulus with exogenous RFRP3-8. Indirect support for such hypothesis comes from our pharmacological testing of the antagonist of RFRP receptors, RF9, in vivo that revealed potent gonadotropin-releasing effects of the antagonist (19) . From a mechanistic standpoint, previous data on the ability of RFRP3 to inhibit electrical activity and c-fos expression in GnRH neurons in mice and rats strongly suggest that the inhibitory responses detected in our in vivo experiments in male and GNX female rats are caused, at least partially, by direct inhibition of this neuronal population (5, 31) . Notably, a recent report in mice suggests that the effects of RFRP3 on GnRH neuronal firing may not be homogeneous, since only ϳ40% of these neurons responded to RFRP3 with rapid and repeatable inhibition in that particular study, whereas even excitatory responses were detected in as much as 12% of this population (5) . This may explain, at least partially, the variability in the nature and magnitude of gonadotropin responses to RFRP3 detected across studies, especially when different species or physiological states are compared. Yet it is to be noted that another study has recently documented more consistent inhibitory responses of GnRH neurons to RFRP3 stimulation (31) .
Despite the original reports in quail, where GnIH was defined by virtue of its ability to suppress LH secretion at the pituitary level (30) , few studies to date had addressed this potential mechanism in mammals. Indeed, although the inhibitory effects of RFRP3 at the pituitary were documented in ovine and bovine species (4, 11) , conflictive results on this front have been obtained in rodents. Our data suggest that, in addition to central levels, RFRP3 is able to act directly at the pituitary, where the octapeptide was capable of decreasing basal and GnRH-stimulated secretion of LH by pituitaries from GNX males. Although in vitro studies would ideally need to be extended to other settings, such as intact rodents and GNX females, comparison of the dose range for effects reported herein reveals a dominant inhibitory action of RFRP3 on GnRH-stimulated LH secretion at the low physiological range (10 Ϫ10 M), which is lost at higher concentrations (10 Ϫ6 M) of the neuropeptide. In fact, the effects of RFRP3 on basal LH secretion had not been demonstrated previously (4, 11, 16) , and in our studies they became consistent only at rather high concentrations, a contention that casts doubt on the physiological relevance of such a phenomenon. Altogether, present and previous (recent) data strongly suggest that RFRP3 is capable of inhibiting GnRH-stimulated LH secretion directly at the pituitary level in a number of species, including the rat, sheep, and cattle. Of note, our data are the first to document the specificity of this effect, as mediated by RFRPR, since the antagonist of these receptors, RF9, was capable of blocking such an action. Overall, this pituitary effect may provide a tenable mechanism for the observed inhibition of gonadotropin secretion following iv injection of RFRP3-8 into GNX male rats (see Fig. 5 ), which is in line with very recent reports in GNX female rats and male calves (11, 21) . Admittedly, however, part of the inhibitory effects of systemic administration of RFRP3-8 may also derive from central actions at hypothalamic sites, such as the median eminence, with high permeability of the blood-brain barrier. This possibility remains to be tested experimentally.
In addition to their potential physiological interest, our current data may also have pharmacological implications, since they provide an in-depth characterization of the gonadotropininhibitory effects of two analogs of RFRP3 as well as the testing of other related peptides. Of interest, in our studies, RFRP3-8 appeared to display preserved, if not higher, biopotency over the longer fragment of RFRP3, RFRP3-17, suggesting that, as predicted in the human and sheep, the octapeptide may be a fully active form of this neuropeptide in the rat. Admittedly, the magnitude of the gonadotropin responses to RFRP3 was globally modest, but the fact that discernible inhibitory actions were detected directly at the pituitary level and after systemic administration of the octapeptide reinforces the possibility of future use of analogs of RFRP3 in the pharmacological manipulation of the gonadotropic axis.
In conclusion, we have provided herein an integral characterization of the gonadotropin-inhibitory actions of RFRP3. To do so, hormonal tests were implemented in male and female rats, either gonadal intact or after being GNX, and LH and FSH responses were recorded at different time points after administration of ranged doses of RFRP3 analogs through different routes of administration. Overall, our results support a putative inhibitory role of RFRP3 as ortholog of GnIH in the regulation of gonadotropin secretion in mammals, which appears to involve direct pituitary actions as well as potential central (hypothalamic) effects. Our results pave the way for future indepth analyses on the potential interplay between RFRP and other excitatory and inhibitory regulators of the gonadotropic axis as well as for the rational design of pharmacological protocols for the therapeutic manipulation of the reproductive axis using derivatives of RFRP3.
